54
Views
5
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Dabigatran etexilate: advances in anticoagulation therapy

&
Pages 771-774 | Published online: 10 Jan 2014
 

Abstract

Evaluation of: Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 361, 2342–2352 (2009).

Venous thromboembolism (VTE) is associated with significant morbidity and mortality. The need for anticoagulation therapy is well recognized, but treatment is frequently suboptimal owing to limitations of current agents. The RE-COVER™ trial compared 150 mg twice-daily dabigatran etexilate (herafter referred to as dabigatran) with warfarin for 6 months in patients with acute VTE; dabigatran was as effective as warfarin in preventing recurrent VTE, with comparable major bleeding and significantly lower total bleeding rates. The Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY®) trial on stroke prevention in patients with atrial fibrillation has also been completed recently, and dabigatran at higher doses showed superior efficacy in preventing stroke and systemic embolism, with lower bleeding than warfarin. Dabigatran provides convenient fixed-dose treatment without the need for monitoring, and has the potential to change the management of venous and arterial thromboembolism.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

The authors want to express their thanks to Boehringer Ingelheim for kindly funding editorial assistance. The authors are also grateful to Rebecca Gardner (Parexel) for her skilled writing assistance and help in tracing relevant references.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.